Validation of Candidate Phospholipid Biomarkers of Chronic Kidney Disease in Hyperglycemic Individuals and Their Organ-Specific Exploration in Leptin Receptor-Deficient db/db Mouse.
chronic kidney disease
diabetic nephropathy
high-fat-diet
leptin receptor-deficient mouse
liver
lungs
metabolomics
prediabetes and type 2 diabetes
reduced kidney function
Journal
Metabolites
ISSN: 2218-1989
Titre abrégé: Metabolites
Pays: Switzerland
ID NLM: 101578790
Informations de publication
Date de publication:
03 Feb 2021
03 Feb 2021
Historique:
received:
15
12
2020
revised:
27
01
2021
accepted:
29
01
2021
entrez:
6
2
2021
pubmed:
7
2
2021
medline:
7
2
2021
Statut:
epublish
Résumé
Biological exploration of early biomarkers for chronic kidney disease (CKD) in (pre)diabetic individuals is crucial for personalized management of diabetes. Here, we evaluated two candidate biomarkers of incident CKD (sphingomyelin (SM) C18:1 and phosphatidylcholine diacyl (PC aa) C38:0) concerning kidney function in hyperglycemic participants of the Cooperative Health Research in the Region of Augsburg (KORA) cohort, and in two biofluids and six organs of leptin receptor-deficient (db/db) mice and wild type controls. Higher serum concentrations of SM C18:1 and PC aa C38:0 in hyperglycemic individuals were found to be associated with lower estimated glomerular filtration rate (eGFR) and higher odds of CKD. In db/db mice, both metabolites had a significantly lower concentration in urine and adipose tissue, but higher in the lungs. Additionally, db/db mice had significantly higher SM C18:1 levels in plasma and liver, and PC aa C38:0 in adrenal glands. This cross-sectional human study confirms that SM C18:1 and PC aa C38:0 associate with kidney dysfunction in pre(diabetic) individuals, and the animal study suggests a potential implication of liver, lungs, adrenal glands, and visceral fat in their systemic regulation. Our results support further validation of the two phospholipids as early biomarkers of renal disease in patients with (pre)diabetes.
Identifiants
pubmed: 33546276
pii: metabo11020089
doi: 10.3390/metabo11020089
pmc: PMC7913334
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Horizon 2020
ID : 19076 & 20679 iPDM-GO
Références
Kidney Blood Press Res. 2018;43(2):522-535
pubmed: 29627840
Biochim Biophys Acta. 2012 Mar;1821(3):425-34
pubmed: 22179025
J Lipid Res. 2006 Aug;47(8):1791-802
pubmed: 16702602
PLoS Genet. 2008 Nov;4(11):e1000282
pubmed: 19043545
Epidemiology. 2014 Mar;25(2):292-9
pubmed: 24487212
Epidemiology. 2000 Sep;11(5):550-60
pubmed: 10955408
PLoS One. 2014 Jan 17;9(1):e85724
pubmed: 24465667
Mol Cell Biol. 2011 Oct;31(20):4205-18
pubmed: 21844222
Eur J Epidemiol. 2018 Jan;33(1):55-66
pubmed: 29181692
Diabetes. 2020 Dec;69(12):2756-2765
pubmed: 33024004
Diabetes Care. 2009 Mar;32(3):424-6
pubmed: 19074997
Nature. 2011 Aug 31;477(7362):54-60
pubmed: 21886157
Int J Exp Pathol. 2011 Dec;92(6):413-21
pubmed: 22118645
Arterioscler Thromb Vasc Biol. 2009 Jun;29(6):850-6
pubmed: 19286635
Horm Metab Res. 2017 Jan;49(1):43-49
pubmed: 27813053
Pharmacol Res. 2016 May;107:372-380
pubmed: 26956523
Mol Cell Endocrinol. 1991 May;77(1-3):217-27
pubmed: 1840041
Int J Mol Sci. 2020 Jul 31;21(15):
pubmed: 32752107
Kidney Int. 2014 Mar;85(3):611-23
pubmed: 24304883
Nephron Clin Pract. 2014;128(3-4):303-11
pubmed: 25531673
Endocrinology. 1983 Mar;112(3):829-37
pubmed: 6822213
Front Endocrinol (Lausanne). 2019 Nov 22;10:818
pubmed: 31824430
Diabetes. 2019 Feb;68(2):248-257
pubmed: 30665953
Nephron. 2019;143(1):38-42
pubmed: 30947190
Am J Physiol Renal Physiol. 2003 Jun;284(6):F1138-44
pubmed: 12736165
Nat Rev Nephrol. 2014 Jul;10(7):379-88
pubmed: 24861084
Am J Physiol Lung Cell Mol Physiol. 2011 Mar;300(3):L430-40
pubmed: 21191108
Diabetes Care. 2018 Dec;41(12):2617-2624
pubmed: 30327364
J Biol Chem. 2011 Aug 12;286(32):28544-55
pubmed: 21669879
J Clin Invest. 1982 Sep;70(3):673-83
pubmed: 6896715
Mol Syst Biol. 2012;8:615
pubmed: 23010998
Diabetes Metab. 2017 Oct;43(5):460-464
pubmed: 28526322
Diabetologia. 2015 Sep;58(9):2133-43
pubmed: 26058503
Diabetes. 2004 Jul;53(7):1831-40
pubmed: 15220208
Nat Rev Drug Discov. 2003 Aug;2(8):668-76
pubmed: 12904817
Diabetes. 2015 Jan;64(1):284-90
pubmed: 25071027
N Engl J Med. 2012 Jul 5;367(1):20-9
pubmed: 22762315
Exp Diabetes Res. 2012;2012:616313
pubmed: 22461787
Exp Biol Med (Maywood). 2005 Feb;230(2):135-43
pubmed: 15673562
Metabolomics. 2018;14(1):18
pubmed: 29354024
Clin J Am Soc Nephrol. 2015 Aug 7;10(8):1371-9
pubmed: 26175542
Metabolism. 2001 Dec;50(12):1435-40
pubmed: 11735089
Arch Biochem Biophys. 2018 May 15;646:90-97
pubmed: 29621522
Mol Cell Biochem. 2010 Jul;340(1-2):125-31
pubmed: 20174962
Am J Physiol Endocrinol Metab. 2014 Mar;306(6):E592-605
pubmed: 24425761
Can J Kidney Health Dis. 2017 May 22;4:2054358117705371
pubmed: 28616250
Lancet. 2020 Feb 29;395(10225):709-733
pubmed: 32061315
Rev Endocr Metab Disord. 2019 Sep;20(3):303-319
pubmed: 31637580
Handb Exp Pharmacol. 2013;(216):373-401
pubmed: 23563667
Am J Physiol Lung Cell Mol Physiol. 2006 May;290(5):L856-65
pubmed: 16373670
Arterioscler Thromb Vasc Biol. 2013 Jul;33(7):1513-20
pubmed: 23640498
Adv Drug Deliv Rev. 2018 Aug;133:66-75
pubmed: 29698625
EBioMedicine. 2016 May;7:121-34
pubmed: 27322466
Diabetologia. 1978 Jul;15(1):59-63
pubmed: 98379
Ann Intern Med. 2013 Jun 4;158(11):825-30
pubmed: 23732715
BMJ. 2010 Nov 08;341:c5869
pubmed: 21059726
J Am Soc Nephrol. 2017 Apr;28(4):1023-1039
pubmed: 28143897